What is the best and worst Takeda drug?

Quote
























“Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared to other treatments,” explained the director of NICE’s health technology evaluation centre, Professor Carole Longson. “We have to be sure that a drug is both effective and cost-effective before it can be recommended.”

Entyvio is a drug therapy designed to treat adults who suffer from moderately to severely active Crohn’s disease, and who have responded inadequately, lost response to, or do not tolerate conventional therapies or a tumor necrosis factor-alpha inhibitor. The company had tried to defend against the first indications that NICE would rule against the drug by agreeing on lowering the drug’s price through a patient access scheme.

pathetic
 








Best
Brintellix, hands down. It has unique MOA and there is nothing else on the market like it.
It's still early with Contrave, but the launch is going very well.

Dexilant is really good, but all the other PPI's have gone generic or over the counter and insurance doesn't want to pay for dexilant if they don't have too.

Worst
This one goes to Amitiza. Docs have told me for years they don't see IBS or constipated patients, but now they write Linzess like crazy. Maybe it's because we aren't once a day, maybe our drug just isn't as good, or a little of both. Takeda has always treated Amitiza like a red headed step child, you will receive very little support selling this drug.

Uloric and Nesina are decent drugs, you will just get beat down in a cost battle every time with those drugs.

Good news, you will get either Brintellix or Contrave most likely, so you will have at least 1 really good drug to sell.
 




Anonymous said:
“Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared to other treatments,” explained the director of NICE’s health technology evaluation centre, Professor Carole Longson. “We have to be sure that a drug is both effective and cost-effective before it can be recommended.”

Entyvio is a drug therapy designed to treat adults who suffer from moderately to severely active Crohn’s disease, and who have responded inadequately, lost response to, or do not tolerate conventional therapies or a tumor necrosis factor-alpha inhibitor. The company had tried to defend against the first indications that NICE would rule against the drug by agreeing on lowering the drug’s price through a patient access scheme.

pathetic
Click to expand...

Are you kidding? Shows you know little about biologics. NICE's guidance in the UK is by no means indicative of what is happening in the states. They say no initially to every expensive biologic. Entyvio is surpassing all expectations. Ask any thought leader who treats IBD.
 




Contrave? Name one, just one clinical advantage it has over its competitors? Less effective, more AEs, more risks, more contraindications, more drug interactions, bid could keep going. Now, you name one advantage. Can't even say cost(which isn't clinical) either because Belviq just lowered their price and Qsymia has just been added to more mc.
 








Wow - there are no bests for Takeda, but I suppose even plants on the forest floor would consider a flashlight a life saver. Get a clue and find a company worth investing your time and effort into.

Sincerely,

The thousands who were smart enough to leave (yes that is thousands)
 












Top Bottom
Back
Quote